ข่าวประชาสัมพันธ์ Acute Coronary Syndromes

New ESC Guidelines Recommend Efient(R) (Prasugrel) as First-line Antiplatelet Therapy for Patients with Non-ST Segment Myocardial Infarction and Unstable Angina Acute Coronary Syndromes

In new guidelines from the European Society of Cardiology (ESC), prasugrel a once daily oral antiplatelet medicine received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI a type of heart attack and unstable angina or UA).(1) The highest available recommendation, Class I recognizes that prasugrel is

01 กันยายน 2554 08:31 น.

New ESC Guidelines Recommend BRILIQUE (ticagrelor) in all Moderate-To-High Risk Patients With Non-ST Elevation Acute Coronary Syndromes

- This release is not intended for US media Ticagrelor Recommended for Medically & Invasively Managed NSTE-ACS Patients Regardless of Prior Treatment with... ส.ค. 54

Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes

- SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The... ส.ค. 52

U.S. Regulators Approve Prasugrel for Reduction of Cardiovascular Events In Patients with Acute Coronary Syndromes Managed with Artery-Opening Procedure

Daiichi Sankyo Company, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient... ก.ค. 52